-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

615.P1.28 615. Acute Myeloid Leukemia: Commercially available Therapy, excluding Transplantation: Poster I

Acute Myeloid Leukemia: Commercially available Therapy, excluding Transplantation Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 5, 2015: 5:30 PM-7:30 PM
Hall A, Level 2 (Orange County Convention Center)

Agnieszka Wierzbowska, MD, PhD1*, Ewa Wawrzyniak, PhD1*, Agnieszka Pluta, MD, PhD1*, Tadeusz Robak, MD, PhD1, Grzegorz J. Mazur, MD, PhD2*, Anna Dmoszynska, MD, PhD3, Jaroslav Cermak, MD, Ph.D.4, Albert Oriol, MD5*, Farhad Ravandi, MD6 and Hagop M. Kantarjian, MD6

1Department of Hematology, Medical University of Lodz, Lodz, Poland
2Department of Internal Disease, Wroclaw Medical University, Wroclaw, Poland
3Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland
4Department of Clinical Hematology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
5Institut Català d’Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
6Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Matthew J. Wieduwilt, MD, PhD1, Scott Thomas, PhD2*, Rebecca L. Olin, MD, MSCE3, Aaron C. Logan, MD PhD4, Lloyd E. Damon, MD3*, Thomas G. Martin III, MD3, McNancy Kang5*, Peter H. Sayre, MD, PhD3, Wanda Boyer, NP, MSN5*, Karin ML Gaensler, MD3, Kirsten Anderson6*, Pamela Munster, M.D.7* and Charalambos Andreadis, MD, MSCE5

1University of California, San Diego, La Jolla, CA
2University of California, San Francisco, San Francisco
3University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
4Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, San Francisco, CA
5Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA
6University of California, Los Angeles, Los Angeles
7Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

Seung-Hwan Shin, M.D.1*, Seung-Ah Yahng, M.D.2*, Jae-Ho Yoon, M.D.3*, Byung-Sik Cho, M.D.4*, Hee-Je Kim, M.D.5, Young-Woo Jeon, M.D.4*, Sung-Eun Lee, M.D.5*, Ki-Sung Eom, M.D.4*, Yoo-Jin Kim, M.D.5, Seok Lee, M.D.5, Chang-Ki Min, M.D.5*, Seok-Goo Cho, M.D.5, Dong-Wook Kim6, Jong-Wook Lee, M.D.5 and Woo-Sung Min, M.D.5*

1Hematology, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
2Hematology, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
3Department of Hematology, Catholic Blood and Marrow Transplantation Center, Cancer Research Institute, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
4Hematology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
5Department of Hematology, Catholic Blood and Marrow Transplantation Center, Cancer Research Institute, Seoul St. Mary’s hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
6Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea

Asma Anwar, MD1, Anna B. Halpern, MD1, Megan Othus, PhD2*, Bart L. Scott, MD2,3, Paul C. Hendrie, MD, PhD4, Pamela S. Becker, MD, PhD4, Andrea M. Perdue, PA-C5*, Heather A. Smith, PA-C5*, Tara L. Chen, PharmD5*, Sarah A. Buckley, MD1*, Kaysey F. Orlowski6*, Morgan A. Powell, BS6*, Elihu H. Estey, MD6,7* and Roland B. Walter, MD, PhD, MS4,6,8

1Hematology/Oncology Fellowship Program, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA
2Fred Hutchinson Cancer Research Center, Seattle, WA
3Department of Medicine/Division of Medical Oncology, University of Washington, Seattle, WA
4Department of Medicine/Division of Hematology, University of Washington, Seattle, WA
5Seattle Cancer Care Alliance, Seattle, WA
6Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
7Division of Hematology, University of Washington, Seattle, WA
8Department of Epidemiology, University of Washington, Seattle, WA

Taiichi Kyo, MD1, Kouhei Kyo, MD1*, Takeshi Okatani, MD1*, Tetsuro Ochi, MD1*, Kayo Toishigawa2*, Ryota Imanaka, MD1*, Yuta Katayama, MD, PhD1* and Mitsuhiro Itagaki, MD1*

1Internal Medicine, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan
2Department of Internal Medicine, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan

Monica Reddy Muppidi, MD1*, Craig W. Freyer, PharmD2*, Laurie Ann Ford1*, Evelena P Ontiveros, MD, PhD1, James E. Thompson, MD1, Elizabeth A. Griffiths, MD1 and Eunice S. Wang, MD1

1Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY
2Department of Pharmacy, Roswell Park Cancer Institute, Buffalo, NY

Benyam Muluneh, PharmD1*, Katie Buhlinger2*, Allison M. Deal, MS3*, Joshua F. Zeidner, MD4, Matthew C. Foster, MD5, Katarzyna Joanna Jamieson, MD5*, Jill Bates, PharmD1* and Hendrik W. Van Deventer, MD5

1Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC
2UNC Eshelman School of Pharmacy, Chapel Hill, NC
3Biostatistics and Clinical Data Management Core, University of North Carolina, Chapel Hill, NC
4Department of Medicine, University of North Carolina, Chapel Hill, NC
5Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

Wontak Kim1*, Katherine K. Soh1*, Jeremiah J. Bearss1*, Ye Sol Lee2*, Peter Peterson, PhD1*, Clifford J. Whatcott, PhD1*, Adam Siddiqui-Jain, PhD3*, Steven Weitman, MD, PhD3*, James M Bogenberger, PhD4, Raoul Tibes, MD, PhD5, David J. Bearss, PhD3 and Steven L. Warner, PhD3

1Discovery Biology, Tolero Pharmaceuticals, Inc., Lehi, UT
2Discovery Biology, Tolero Pharmaceuticals, Lehi, UT
3Tolero Pharmaceuticals, Inc., Lehi, UT
4Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ
5Mayo Clinic Scottsdale Arizona, Scottsdale, AZ

Mark Lee, MD, PhD1 and Sung-Yong Kim, MD2*

1hematology/Oncology, Konkuk University Medical Center, Seoul, South Korea
2Hematology/Oncology, Konkuk University Medical Center, Seoul, South Korea

*signifies non-member of ASH